You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEthynodiol diacetate
Accession NumberDB00823  (APRD00760)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic progestational hormone used alone or in combination with estrogens as an oral contraceptive. Although etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug that has never been marketed).
Structure
Thumb
Synonyms
17α-Ethynyl-19-norandrost-4-ene-3β,17-beta-diol diacetate
17α-Ethynyl-3,17-dihydroxy-4-estrene diacetate
17α-Ethynyl-4-estrene-3β,17β-diol diacetate
17α-Ethynylestr-4-ene-3β,17β-diol acetate
19-Nor-17α-pregn-4-en-20-yne-3β,17-diol diacetate
3β, 17β-Diacetoxy-17α-ethynyl-4-oestrene
3β,17β-Diacetoxy-19-nor-17α-pregn-4-en-20-yne
Ethynodiol
Etinodiol
Étynodiol
Etynodiol
Etynodiol acetate
Etynodiolum
External Identifiers
  • CB 8080
  • SC 11800
  • SC-11800
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ConovaSearle
ContinuinNot Available
DernulenSearle
FemulenPfizer
LuteonormNot Available
Luto-MetrodiolNot Available
MetrodiolNot Available
Brand mixtures
NameLabellerIngredients
Demulen 30 (21 Day Pack)Pfizer Canada Inc
Demulen 30 (28 Day Pack)Pfizer Canada Inc
Demulen 50 (21 Day Pack)Pfizer Canada Inc
Demulen 50 (28 Day Pack)Pfizer Canada Inc
Kelnor 1/35Physicians Total Care, Inc.
Zovia 1/35Mayne Pharma Inc.
Zovia 1/35e-28Actavis Pharma, Inc.
Zovia 1/50e-28Actavis Pharma, Inc.
SaltsNot Available
Categories
UNII62H10A1236
CAS number297-76-7
WeightAverage: 384.5085
Monoisotopic: 384.230059512
Chemical FormulaC24H32O4
InChI KeyONKUMRGIYFNPJW-KIEAKMPYSA-N
InChI
InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1
IUPAC Name
(1S,2R,5S,10R,11S,14R,15S)-5-(acetyloxy)-14-ethynyl-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl acetate
SMILES
[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[[email protected]](OC(C)=O)C=C3CC[C@@]21[H]
Pharmacology
IndicationFor the prevention of pregnancy in women who elect to use this product as a method of contraception.
Structured Indications
PharmacodynamicsEthynodiol Diacetate is used as a female contraceptive. Ethynodiol Diacetate is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Ethynodiol Diacetate tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.
Mechanism of actionBinds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Ethynodiol Diacetate will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.
TargetKindPharmacological actionActionsOrganismUniProt ID
Progesterone receptorProteinyes
agonist
HumanP06401 details
Estrogen receptorProteinyes
agonist
HumanP03372 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding50-85%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Ethynodiol diacetate.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
AcenocoumarolEthynodiol diacetate may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethynodiol diacetate.Withdrawn
AcitretinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Ethynodiol diacetate.Experimental
AlitretinoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
AmobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Amobarbital.Approved, Illicit
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Ethynodiol diacetate.Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Ethynodiol diacetate.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Ethynodiol diacetate.Approved
AprepitantThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Ethynodiol diacetate.Approved, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
ArtemetherThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Artemether.Approved
AtazanavirThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Atazanavir.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ethynodiol diacetate.Investigational
BarbexacloneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbital.Illicit
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
BexaroteneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Bexarotene.Approved, Investigational
BexaroteneThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Bexarotene.Approved, Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
BoceprevirThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Boceprevir.Approved
BosentanThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Bosentan.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ethynodiol diacetate.Withdrawn
C1 Esterase Inhibitor (Human)Ethynodiol diacetate may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Ethynodiol diacetate may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
CarbamazepineThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Carbamazepine.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethynodiol diacetate.Experimental
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Ethynodiol diacetate.Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ethynodiol diacetate.Approved
CholestyramineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Cholestyramine.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethynodiol diacetate.Experimental
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Ethynodiol diacetate.Nutraceutical, Vet Approved
ClobazamThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Clobazam.Approved, Illicit
CobicistatThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Colestipol.Approved
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Ethynodiol diacetate.Approved
DabrafenibThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Dabrafenib.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Ethynodiol diacetate.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Ethynodiol diacetate.Approved, Withdrawn
DarunavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Darunavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ethynodiol diacetate.Investigational
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Ethynodiol diacetate.Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Ethynodiol diacetate.Approved, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Ethynodiol diacetate.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Ethynodiol diacetate.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Ethynodiol diacetate.Approved
DicoumarolEthynodiol diacetate may decrease the anticoagulant activities of Dicoumarol.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethynodiol diacetate.Approved
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Ethynodiol diacetate.Approved, Vet Approved
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Ethynodiol diacetate.Approved
EfavirenzThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Ethynodiol diacetate.Approved
Eslicarbazepine acetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethyl biscoumacetateEthynodiol diacetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Exenatide.Approved, Investigational
FelbamateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Felbamate.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ethynodiol diacetate.Approved
FluindioneEthynodiol diacetate may decrease the anticoagulant activities of Fluindione.Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Ethynodiol diacetate.Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Ethynodiol diacetate resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Fosphenytoin.Approved
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Ethynodiol diacetate.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethynodiol diacetate.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ethynodiol diacetate.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethynodiol diacetate.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ethynodiol diacetate.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethynodiol diacetate.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Ethynodiol diacetate.Approved
GriseofulvinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ethynodiol diacetate.Investigational
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Hexobarbital.Approved
HirulogThe therapeutic efficacy of Hirulog can be decreased when used in combination with Ethynodiol diacetate.Experimental
idraparinuxThe therapeutic efficacy of idraparinux can be decreased when used in combination with Ethynodiol diacetate.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethynodiol diacetate.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethynodiol diacetate.Approved
IsotretinoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Isotretinoin.Approved
LamotrigineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lamotrigine.Approved, Investigational
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ethynodiol diacetate.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethynodiol diacetate.Approved
LopinavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lopinavir.Approved
LumacaftorThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lumacaftor.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate.Approved
MethohexitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Methylphenobarbital.Approved
MetreleptinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ethynodiol diacetate.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ethynodiol diacetate.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
Mycophenolic acidThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mycophenolic acid.Approved
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Ethynodiol diacetate.Approved
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Ethynodiol diacetate.Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
NelfinavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nelfinavir.Approved
NevirapineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nevirapine.Approved
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Ethynodiol diacetate.Investigational
OxcarbazepineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Oxcarbazepine.Approved
PentobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Ethynodiol diacetate.Approved
PerampanelThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Perampanel.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ethynodiol diacetate.Approved, Withdrawn
PhenindioneEthynodiol diacetate may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Phenobarbital.Approved
PhenprocoumonEthynodiol diacetate may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
PrimidoneThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Primidone.Approved, Vet Approved
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Ethynodiol diacetate.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Ethynodiol diacetate.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Ethynodiol diacetate.Approved
PrucaloprideThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Prucalopride.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Ethynodiol diacetate.Approved
RifabutinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Rifapentine.Approved
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Ethynodiol diacetate.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
SaquinavirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved
SecobarbitalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ethynodiol diacetate.Approved, Investigational, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
St. John's WortThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with St. John's Wort.Nutraceutical
SugammadexThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Sugammadex.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
TelaprevirThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Telaprevir.Approved
ThalidomideEthynodiol diacetate may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Ethynodiol diacetate.Investigational
ThiopentalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiopental.Approved, Vet Approved
TipranavirThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Tipranavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethynodiol diacetate.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethynodiol diacetate.Approved
TopiramateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Topiramate.Approved
Tranexamic AcidEthynodiol diacetate may increase the thrombogenic activities of Tranexamic Acid.Approved
TretinoinThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Ethynodiol diacetate.Withdrawn
UlipristalThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Ulipristal.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational
VoriconazoleThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinEthynodiol diacetate may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Ethynodiol diacetate.Approved, Investigational, Withdrawn
Ym150The therapeutic efficacy of Ym150 can be decreased when used in combination with Ethynodiol diacetate.Investigational
Food InteractionsNot Available
References
Synthesis Reference

Klimstra, P.D.; U.S. Patent 3,176,013; March 30, 1965; assigned to G.D. Searle & Co.

General ReferencesNot Available
External Links
ATC CodesG03FA06G03AA01G03DC06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.9399
Caco-2 permeable+0.6125
P-glycoprotein substrateSubstrate0.5754
P-glycoprotein inhibitor IInhibitor0.8432
P-glycoprotein inhibitor IIInhibitor0.619
Renal organic cation transporterNon-inhibitor0.8131
CYP450 2C9 substrateNon-substrate0.8497
CYP450 2D6 substrateNon-substrate0.9139
CYP450 3A4 substrateSubstrate0.7647
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6524
CYP450 2D6 inhibitorNon-inhibitor0.9519
CYP450 2C19 inhibitorNon-inhibitor0.7671
CYP450 3A4 inhibitorNon-inhibitor0.6564
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8322
Ames testNon AMES toxic0.9651
CarcinogenicityNon-carcinogens0.9119
BiodegradationNot ready biodegradable0.963
Rat acute toxicity2.1783 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9037
hERG inhibition (predictor II)Non-inhibitor0.8353
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
Kit
KitOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point126-127Klimstra, P.D.; U.S. Patent 3,176,013; March 30, 1965; assigned to G.D. Searle & Co.
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00397 mg/mLALOGPS
logP3.99ALOGPS
logP3.69ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.62 m3·mol-1ChemAxon
Polarizability44.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Estrane-skeleton
  • Delta-4-steroid
  • Ynone
  • Acetate salt
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
  • terminal acetylenic compound (CHEBI:31580 )
  • steroid ester (CHEBI:31580 )
  • C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C12724 )
  • C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030124 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Tamaya T, Nioka S, Furuta N, Shimura T, Takano N: Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84. [PubMed:858280 ]
  2. Briggs MH: Contraceptive steroid binding to the human uterine progesterone-receptor. Curr Med Res Opin. 1975;3(2):95-8. [PubMed:166800 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kappus H, Bolt HM, Remmer H: Affinity of ethynyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. J Steroid Biochem. 1973 Mar;4(2):121-8. [PubMed:4123746 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23